Please use this identifier to cite or link to this item:
Effects of Caffeine and High-Fat Diet on Blood Glucose, Akt Activity and Chromium Contents in C57BL/6JNarl Mice
|關鍵字:||Caffeine;咖啡因;High fat diet;Blood glucose;Akt;Chromium;高脂飲食;血糖;Akt;鉻||出版社:||獸醫學系暨研究所||引用:||參考文獻 1. 衛生署 第三次國民營養調查 1993-1996. 2. Aguiar LM, Nobre HV Jr, Macedo DS, Oliveira AA, Freitas RM, Vasconcelos SM, Cunha GM, Sousa FC and Viana GS. Neuroprotective effects of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol Biochem Behav 84: 415-9, 2006. 3. Akiba T, Yaguchi K, Tsutsumi K, Nishioka T, Koyama I, Nomura M, Yokogawa K, Moritani S and Miyamoto K. Inhibitory mechanism of caffeine on insulin-stimulated glucose uptake in adipose cells. Biochem Pharmacol 68: 1929-1937, 2004. 4. Anderson RA. Chromium metabolism and its role in disease processes in man. Clin Physiol Biochem 4: 31-41,1986. 5. Anderson RA. Recent advances in the clinical and biochemical effects of chromium deficiency. Prog Clin Biol Res 380: 221-234, 1993. 6. Anderson RA. Chromium, glucose intolerance and diabetes. J Am Coll Nutr 17: 548-555, 1998. 7. Anderson RA. Chromium in the prevention and control of diabetes. Diabetes Metab 26: 22-27, 2000. 8. Andreelli F, Laville M, VegaN, Riou JP, Vidal H. Regulation of gene expression during severe caloric restriction: lack of induction of p85 alpha phosphatidylinositol 3- kinase mRNA in skeletal muscle of patients with type II(non-insulin dependent) diabetes mellitus. Diabetologia 43: 353-363, 2000. 9. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponecitn, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999. 10. Arner P, Pollare T, Lithell H, Livingston JN. Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2(non-insulin-dependent) diabetes mellitus. Diabetologia 30: 437-440, 1987 11. Arner P. Insulin resistance in type 2 diabetes – role of the adipokines. Curr Mol Med 5:333-339, 2005. 12. Axelsson J, and Thesleff S. Activation of the contractile mechanism in striated muscle. Acta Physiol Scand 44: 55–66, 1958. 13. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Lazar MA. Regulation of fasted blood glucose by resistin. Science 303: 1195-1198, 2004 14. Battram DS, Graham TE, Richter EA, Dela F. The effect of caffeine on glucose kinetics in humans-influence of adrenaline. J Physiol 569: 347-355, 2005. 15. Baylin A, Hernandez-Diaz S, Kabagambe EK, Siles X and Campos H. Transient Exposure to Coffee as a Trigger of a First Nonfatal Myocardial Infarction. Epidemology 17: 506-511, 2006. 16. Beavo JA, Rogers NL, Crofford OB, Hardman JG, Sutherland EW and Newman EV. Effects of xanthine derivatives on lipolysis and on adenosine 3, 5-monophosphate phosphodiesterase activity. Mo Pharmacol 6: 597–603, 1970. 17. Blasina A, Price BD, Turenne GA and McGowan CH. Caffeine inhibits the checkpoint kinase ATM. Curr Biol 9: 1135–1138, 1999. 18. Bonati M, Latini R, Galletti F, Young JF, Tognoni G and Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther 32: 98–106, 1982. 19. Boozer CN, Schoenbach G, Atkinson RL. Dietary fat and adiposity: A dose-relationship in adult male rats fed isocalorically. Am J Physiol 268: E546-E550, 1995. 20. Boursier V. Metabolic symdrome. Rivew J Mal Vasc. 31: 190-201, 2006. 21. Brachtel D, and Richter E. Absolute bioavailability of caffeine from a tablet formulation. J Hepatol 16: 385, 1992. 22. Brautigan DL, Kruszewski A, Wang H. Chromium and vanadate combination increases insulin-induced glucose uptake by 3T3-L1 adipocytes. Biochem Biophys Res Commun 347: 769-73, 2006. 23. Butcher RW, and Sutherland EW. Adenosine 3,5-phosphate in biological materials. I. Purification and properties of cyclic 3, 5-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3, 5-phosphate in human urine. J Biol Chem 237: 1244–1250, 1962. 24. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in world wide populations. Endocrinol Metab Clin North Am 33: 351-375, 2004. 25. Cheatham B and Kahn CR. Insulin action and the insulin signaling network. Endocr Rev 16: 117-142, 1995 26. Chen G, Liu P, Pattar GR, Tackett L, Bhonagiri P, Strawbridge AB, Elmendorf JS. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism. Mol Endocrinol 20: 857-870, 2006. 27. Chuang LM, Mao FC, Tai TY. Effect of chromium chloride GRT milk powder supplement on gene expression of insulin signaling molecules in KK/HIJ diabetic mice. 25th Annual Meeting The Endocrinology Society & Diabetes Association of the Republic of China 89. 2004. 28. Clifford MN. Chlorogenic acid and other cinnamates-nature, occurrence, dietary burden, absorption and metabolism. J Sci Food Agric 80: 1033-1043, 2000. 29. Clodfelder BJ, Upchurch RG, Vincent JB. A comparision of the insulin-sensitive transport of chromium in healthy and model diabetic rats. J Inorg Biochem 98: 522-533, 2004. 30. Collins S, Martin TL, Surwit RS, Robidoux J. Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics. Physiol Behav 81: 243-248, 2004. 31. Crews HM, Olivier L, and Wilson LA. Urinary biomarkers for assessing dietary exposure to caffeine. Food Addit Contam 18: 1075–1087, 2001. 32. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawate T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105: 311-320, 2000. 33. Czech MP, Corvera S. Signaling mechanisms that regulate glucose transport. J Biol Chem 274: 1865-1868, 1999. 34. Davis CM, Vincent JB. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry 36: 4382-4385, 1997. 35. Deleu D, Jacob P, Chand P, Sarre S and Colwell A. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology 67: 897-9, 2006. 36. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lanacet 365: 1415-1428, 2005. 37. Erickson MA, Schwarzkopf RJ, Mckenzie RD. Effects of caffeine, fructose, and glucose ingestion on muscle glycogen utilization during exercise. Med Sci Sports Exerc 19: 579-583, 1987. 38. Fisone G, Borgkvist A, Usiello A. Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 61: 857-872, 2004. 39. Foukas LC, Daniele N, Ktori C, Anderson KE, Jensen J and Shepherd PR. Direct effects of caffeine and theophylline on p 110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem 277: 37124–37130, 2002. 40. Fredholm BB, Bättig K, Holmén J, Nehlig A and Zvvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51: 83–133, 1999. 41. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura L. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426-430, 2005. 42. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM, Ciaraldi TP. Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest 87: 1072-1081, 1991. 43. Gerdom LE, Goff HM. Ligation modes for nicotinic acid binding to the chromium(Ⅲ) salen complex. Inorg Chem 21: 3847-3848, 1982. 44. Goodyear LE, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95: 2195-2204, 1995. 45. Greer F, Hudson R, Ross R and Graham T. Caffeine ingestion decreases glucose disposal during a hyperinsulinemic-euglycemic clamp in sedentary humans. Diabetes 50: 2349-2354, 2001. 46. Guallar E, Jimenez FJ, van’t Veer P, Bode P, Riemersma RA, Gomez-Aracena J, Kark JD, Arab L, Kok FJ, Martin-Moreno JM. Low toenail chromium concentration and increased risk of nonfatal myocardial infarction. Am J Epidemiol 162: 157-164, 2005. 47. Hanson RL, Imperoatore G, Bennett PH and Knowler WC. Components of the metabolic syndrome and incidence of type 2 diabetes. Diabetes 51: 3120-3127, 2002. 48. Haylock SJ, Buckley PD, Blackwell LF. Separation of biologically active chromium-containing complexes from yeast extracts and other sources of glucose tolerance factor (GTF) activity. J Inorg Biochem 18: 195-211, 1983. 49. Hill MM, Clark SF, Tucker Df, Birnbaum MJ, James DE, Macaulay SL. A role for protein kinase Bβ/Akt2 in insulin-stimulated GLUT4 translocation in adipocytes. Mol Cell Biol 19: 7771-7781, 1999. 50. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR and Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291: 2847-50, 2004. 51. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insuli resistance. Science 259: 87-91, 1993. 52. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372: 746-754, 1994. 53. Hubbard SR. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBOJ 16: 5572-5581, 1997. 54. International Diabetes Federation. The IDF consensus world wide definition of the metabolic syndrome. 2005. 55. Ip C, Trpperman HM, Holohan P, et al. Insulin binding and insulin response of adipocytes from rats adapted to fat feeding. J Lipid Res 17: 588-599, 1976. 56. JazetIM, Pijl H, Frolich M, Romijn JA and Meinders AE. Two days of a very low calorie diet reduces endogenous glucose production in obese type 2 diabetic patients despite the withdrawal of blood glucose-lowering therapies including insulin. Metabolism 54: 705-712, 2005 57. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS and Shader RI. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 37: 693–703, 1997. 58. Kasvinsky PJ, Madsen N.B, Sygusch J and Fletterick RJ. The regulation of glycogen phosphorylase a by nucleotide derivatives. Kinetic and x-ray crystallographic studies. J Biol Chem 253: 3343–3351, 1978. 59. Kasvinsky PJ, Shechosky S and Fletterick RJ. Synergistic regulation of phosphorylase a by glucose and caffeine. J Biol Chem 253: 9102–9106, 1978. 60. Kerr D, Everett J. Coffee, diabetes and insulin sensitivity. Diabetologia 48: 1418, 2005. 61. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548-2556, 2004. 62. Kihlman B, and Overgaard–Hansen K. Inhibition of muscle phosphorylase by methylated oxypurines. Exp Cell Res 8: 252–255, 1955. 63. Kobayashi M, Soman G and Graves DJ. A comparison of the activator sites of liver and muscle glycogen phosphorylase b. J Biol Chem 257: 14041–14047, 1982. 64. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 49: 31372-31378, 1996. 65. Kovacs P, Stumvoll M. Fatty acids and insulin resistance in muscle and liver. Best Pract Res Clin Endocrinol Metab 19: 625-635, 2005. 66. Krook A, Roth RA, Jiang XJ, Zierath JR, Wallberg-Henriksson H. Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes 47: 1281-1286, 1998. 67. Lam K, Carpenter CL, Ruderman NB, Friel JC and Kelly KL. The phosphatidylinositol 3-kinase serine kinase phosphorylates IRS-1. Stimulation by insulin and inhibition by wortmannin. J Biol Chem 269: 20648–20652, 1994. 68. Lamson DS, Plaza SM. The safety and efficacy of high-dose chromium. Altern Med Rev 7: 218-235, 2002. 69. Lau CE, Falk JL. Dose-dependent surmountability of locomotor activity in caffeine tolerance. Pharmacol Biochem Behav 52: 139-43, 1995. 70. Lebovitz HE. Rationale for and role of thazolidinediones in type 2 diabetes mellitus. Am J Cardiol 90: 34-41, 2002. 71. Lee S, Hudson R, Kilpatrick K, Graham TE, Ross R. Caffeine ingestion is associated with reductions in glucose uptake independent of obesity and type 2 diabetes before and after exercise training. Diabetes Care 28: 566-572, 2005. 72. Lelo A, Miners JO, Robson RA and Birkett DJ. Quantitative assessment of caffeine partial clearances in man. Br J Clin Pharmacol 22: 183–186, 1986. 73. Liguori A, Hughes JR, and Grass JA. Absorption and subjective effects of caffeine from coffee, cola, and capsules. Pharmacol Biochem Behav 58: 721–726, 1997. 74. Machalinski B, Walczak M, Syrenicz A, Machalinska A, Grymula K, Stecewicz I, Wiszniewska B, Dabkowska E. Hypoglycemic potency of novel trivalent chromium in hyperglycemic insulin-deficient rats. J Trace Elem Med Biol 20: 33-39, 2006. 75. Magkos F and Kavouras SA. Caffeine use in sports, pharmacokinetics in man, and cellular mechanisms of action. Crit Rev Food Sci Nutr 45: 535-562, 2005. 76. Marshall JA, Hoag S, Shetterly S, et al. Dietary fat predicts conversion from impaired glucose tolerance to NIDDM: The San Luis Valley Diabetes Study. Diabetes Care 17: 50-56, 1994. 77. McFarlane SI, Banerji M and Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86: 713-718, 2001. 78. Mertz W, Toepfer EW, Roginski EE and Polansky MM. Present knowledge of the role of chromium. Fed Proc 33: 2275-2280, 1974. 79. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrionl Metab 82: 4196-4200, 1997. 80. Morris BW, Gray TA, Macneil S. Glucose-dependent uptake of chromium in human and rat insulin-sensitive tissues. Clin Sci(Lond) 84: 477-482, 1993. 81. Muller JE. Circadian variation and triggering of acute coronary events. Am Heart J 137:S1-S8, 1999. 82. Mumford GK, Benowitz NL, Evans SM, Kaminski BJ, Preston KL, Sannerud CA, Silverman K and Griffiths RR. Absorption rate of methylxanthines following capsules, cola and chocolate. Eur J Clin Pharmacol 51:319–325, 1996. 83. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ and Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-55, 2006. 84. Oscai LB, Brown MM, Miller WC. Effect of dietary fat on food intake, growth and body composition in rats. Growth 48: 415-424, 1984. 85. Patti ME and Kahn CR. The insulin receptor-a critical link in glucose homeostasis and insulin action. J Basic Clin Physiol Pharmacol 9: 89-109, 1998. 86. Pessin JE and Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106:165-169, 2000. 87. Petro AE, Cotter J, Cooper DA, Peters JC, Surwit SJ and Surwit RS. Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism 53: 454-457, 2004. 88. Rajpathak S, Rimm EB, Li T, Morris JS, Stampfer MH, Willett WC, Hu FB. Lower toenail chromium in men with diabetes and cardiovascular disease compared with healthy men. Diabetes Care 27: 2211-2216, 2004. 89. Reaven GM. Banting lecture role of insulin resistance in human disease. Diabetes 37: 1595-1607, 1988. 90. Rodriguez de Sotillo DV, Hadley M. Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J Nutr Biochem 13:717-726, 2002. 91. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28: 2130-2135, 2005. 92. Rondinone CM, Wang LM, Lonnroth P, Wesslau C, Pierce JH, Smith U. Insulin receptor substrate(IRS)1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 94: 4171-4175, 1997. 93. Rousseau E, Ladine J, Liu QY and Meissner G. Activation of the Ca2+ release channel of skeletal muscle sarcoplasmic reticulum by caffeine and related compounds. Arch Biochem Biophys 267:75–86, 1998. 94. Salazar-Martinez E, Willett WC and Ascherio A. Coffee consumption and risk for type 2 diabetes mellitus. Ann Intern Med 140: 1-8, 2004. 95. Satiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104: 517-529, 2001. 96. Saltiel AR, Kahn C. Insulin signaling and the regulation of glucose and lipid metabolism. Nature 414: 799-806, 2001. 97. Sanger F. The terminal peptides of insulin. Biochem J 45: 563-574, 1949. 98. Schwarz K, Metz M. A glucose tolerance factor and its differentiation from factor 3. Arch Biochem Biophys 72: 515-518, 1957. 99. Schwarz K, Metz M. Chromium(Ⅲ) and the glucose tolerance factor. Arch Biochem Biophys 85: 292-295, 1959. 100. Seidell JC. Obesity, insulin resistance and diabetes-a world wide epidemic. Br J Nutr Mar 83: S5-8, 2000. 101. Shearer J, Farah A, de Paulis T. Quinides of roasted coffee enhance insulin action in conscious rats. J Nutr 133: 3529-3532, 2003. 102. Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signaling. Biochem J 333: 471-490, 1998. 103. Shinde UA, Sharma G, Xu Yan J, Dhalla Naranjan S, Goyal Ramesh K. Anti-diabetic activity and mechanism of action of chromium chloride. Exp Clin Endocrinol Diabetes 112: 248-252, 2004. 104. Speakman JR. Obesity: the integrated roles of environment and genetics. J Nutr 134: 2090-2105, 2004. 105. Spriet LD, Maclean D, Yck DD, Hultman E, Cederblad G. Effects of caffeine on muscle glycogenolysis and actyl group metabolism during prolonfed exercise in humans. Am J Physio press, 1992. 106. Storlien LH, James DE, Burleigh KM, et al. Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol 251: 576-583, 1986. 107. Svilaas A, Sakhi AK, Andersen LF. Intakes of antioxidants in coffee, wine, and vegetables are correlated with plasma carotenoids in humans. J Nutr 134: 562-567, 2004. 108. Tang W, Sencer S and Hamilton SL. Calmodulin modulation of proteins involved in excitation-contraction coupling. Front Biosci 7: D1583–1589, 2002 109. Thong FS and Graham TE. Caffeine-induced impairment of glucose tolerance is abolished by betaadrenergic receptor blockade in humans. J Appl Physiol 92: 2347-2352, 2002. 110. Thong FSL, Derave W, Kiens B, Graham TE, Urso B, Wojtaszewski JFP, Hansen BF, Richter EA. Caffeine-induced impairment of insulin action but not insulin signaling in human skeletal muscle is reduced by exercise. Diabetes 51: 583-590, 2002. 111. Tokin A. The metabolic syndrome – a growing problem. Eur Heart J 6: A37-A42, 2004. 112. Ueki K, Yamamoto-Honda R, Kaburagi Y, Yamauchi T et al. Potential role of protein kinase B in insulin-induced glucose transport, glycogen synthesis, and protein synthesis. J Biol Chem 273: 5315-5322, 1998. 113. van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 294: 97-104, 2005. 114. Vanhaesebroeck B and Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253: 239–254, 1999. 115. Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz EJ, Strader CD, Davis HR Jr. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 99: 385-90, 1997. 116. Vestergaard H, Bjorbaek C, Hansen T, Larsen FS, Granner DK, Pedersen O. Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients. J Clin Invest 96: 2639-2645, 1995. 117. Vestergaard H, Lund S, Larsen FS, Bjerrum OJ, Pedersen O. Glycogen synthase and phosphofructokinase protein and mRNA levels in skeletal muscle from insulin-restant patients with non-insulin-dependent diabetes mellitus. J Clin Invest 91: 2342-2350, 1993. 118. Vincent JB. Relationship between glucose tolerance factor and low-molecular-weight chromium-binding substance. J Nutr 124: 117-119, 1994. 119. Vrtovec M, Vrtovec B, Briski A, Kocijancic A, Anderson RA, Radovancevic B. Chromium supplementation shortens QTc interval dutaiton in patients with type 2 diabetes mellitus. Am Heart J 149: 632-636, 2005. 120. Walker KS, Deak M, Paterson A, Hudson K, Cohen P, Alessi DR. Activation of protein kinase β and γ isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase Bα. Biochem J 331: 299-308, 1998. 121. Weber A, Herz R and Reiss I. The regulation of myofibrillar activity by calcium. Proc R Soc Lond B Biol Sci 160: 489–499, 1964. 122. Wei JN, Sung FC, Lin CC, Lin RS, Chiang CC and Chuang LM. National surveillance for type 2 diabetes mellitus in Taiwanese children. JAMA 290: 1345-1350, 2003. 123. Weishaar RE, Cain MH and Bristol JA. A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem 28: 537–545, 1985. 124. White MF, Kahn CR. The insulin signaling system. J Biol Chem 269: 1-4, 1994. 125. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 28: 1047-1053, 2004. 126. Willich SN, Maclure M, Mittleman M, Arntz HR, Muller JE. Sudden cardiac death. Support foe a role of triggering in causation. Circulaiton 86: 1442-1450, 1993. 127. Yamamoto A, Wada O, Ono T. Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver. Eur J Biochem 165: 627-631, 1987. 128. Yang X, Palanichamy K, Ontko AC, Rao MN, Fang CX, Ren J, Sreejayan N A newly synthetic chromium complex-chromium(phenylalanine)3 improves insulin responsiveness and reduces whole body glucose tolerance. FEBS Lett 579: 1458-1464, 2005. 129. Zhang XP, Hintze T. cAMP signal transduction induces eNOS activation by promoting PKB phosphorylation. Am J Physiol Heart Circ Physiol 290: H2376-H2384, 2006. 130. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425-432, 1994.||摘要:||
Since caffeine and high-fat diet both can cause blood glucose increase and insulin secretion, and insulin can help blood glucose to get into cells. Therefore, this study was aimed to investigate the intracellular interaction between caffeine and high-fat diet. C57BL/6JNarl mice were fed on low-fat and high-fat diet to evaluate effects of caffeine on blood glucose and Akt activity. Results indicated that body fat, blood glucose and total Akt were significantly increased in high-fat diet (HFD) group. However Akt-pSer473 did not increased, especially in muscle tissue. After caffeine injection, blood glucose concentrations were spiking higher in HFD group and Akt-pSer473 contents were also increased in liver and fat, but not in muscle. It seems that high-fat diet blocks Akt activation in muscle, but not in liver and fat tissue. It is suggested that the obese subjects should be careful about caffeine uptake to avoid blood glucose spiking. Chromium is known can help insulin function in type 2 diabetic subjects. After caffeine injection, it was found that chromium in metabolic tissue is significantly lowered in HFD group, but not in normal diet group. It is suggested that the muscle chromium decreasing in HFD group's tissue may impede the Akt activation.
|Appears in Collections:||獸醫學系所|
Show full item record
TAIR Related Article
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.